MedTrace Logo

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

NCT02400437 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-09-02

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a drug called ixazomib (also known as MLN9708) in combination with dexamethasone and rituximab (the regimen is called IDR) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).

Conditions

  • Waldenstrom's Macroglobulinemia

Interventions

DRUG

Ixazomib

Doses given on Days 1, 8, and 15 in induction and maintenance cycles.

DRUG

Dexamethasone

Doses given on Days 1, 8, and 15 in induction and maintenance cycles.

DRUG

Rituximab

Doses given on Day 1 of induction and maintenance cycles.

Sponsors & Collaborators

Principal Investigators

  • Jorge J. Castillo, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02400437 on ClinicalTrials.gov